LPL Financial LLC Grows Stock Position in Repligen Corporation (NASDAQ:RGEN)

LPL Financial LLC lifted its stake in Repligen Corporation (NASDAQ:RGEN) by 6.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,405 shares of the biotechnology company’s stock after buying an additional 2,168 shares during the period. LPL Financial LLC owned approximately 0.06% of Repligen worth $4,212,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its stake in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after purchasing an additional 743,815 shares during the last quarter. Champlain Investment Partners LLC grew its stake in shares of Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock worth $222,176,000 after purchasing an additional 122,595 shares during the last quarter. Conestoga Capital Advisors LLC grew its stake in shares of Repligen by 3.4% in the first quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company’s stock worth $124,727,000 after purchasing an additional 32,665 shares during the last quarter. Point72 Asset Management L.P. grew its stake in shares of Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after purchasing an additional 594,189 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in shares of Repligen by 7.6% in the first quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company’s stock worth $79,574,000 after purchasing an additional 43,946 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $126.64 on Friday. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average price is $122.58 and its 200-day moving average price is $133.33. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The stock has a market cap of $7.12 billion, a P/E ratio of -506.54, a P/E/G ratio of 2.34 and a beta of 1.05.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%. The company had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. During the same period in the prior year, the firm earned $0.40 earnings per share. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Equities research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, Director Martin D. Madaus purchased 1,800 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director directly owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RGEN. JPMorgan Chase & Co. cut their target price on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Stephens raised Repligen to an “overweight” rating and set a $160.00 target price on the stock in a research note on Tuesday, July 22nd. Royal Bank Of Canada raised their target price on Repligen from $193.00 to $204.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 30th. Wolfe Research raised Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a research report on Tuesday, April 29th. Finally, Evercore ISI cut their price objective on Repligen from $140.00 to $130.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.